Abbott and Women as One Partner to Help More Underrepresented Physicians Lead Clinical Trials

 
 
  • New partnership will provide physician training to drive improved diversity in clinical trials
  •  
  • Training program is open to underrepresented groups including female, Black, Native American, Asian, South Asian, Hispanic and non-binary cardiologists
  •  
  • Provides opportunities for underrepresented physicians to receive training on the clinical trials process, learn new skills, expand their networks and increase visibility with industry partners
  •  

Abbott (NYSE: ABT) today announced a new partnership with Women as One to launch a new program designed to train more female and underrepresented physicians to pursue clinical trial research and help recruit clinical trial participants from historically underrepresented groups.

 

Women as One is a nonprofit organization with the mission to promote talent in medicine by providing women physicians with unique professional opportunities. Abbott provided funding to develop a new program called CLIMB Research, which provides skills training for underrepresented cardiologists.

 

The new program builds upon Abbott's diversity in clinical trials initiative that was established in 2021 to further develop and create a more inclusive clinical trial ecosystem in the U.S.

 

Research shows there is systemic underrepresentation of women and under-resourced populations such as Hispanic and Black participants in clinical trials 1,2 . By training physicians, Abbott, in conjunction with Women as One, is helping close the gaps and overcome the existing barriers to clinical trial participation: lack of trust, lack of access, lack of understanding and lack of a common language.

 

Through six monthly sessions, which include a mix of instruction, case reviews and group discussions, participants in the new CLIMB Research skills training program will receive:

 
  •   Global Connection Among Underrepresented Physicians
    Learn new skills, expand their networks and increase visibility with industry partners.
  •  
  •   In-Depth Knowledge from Experts in the Field
    Enhanced curriculum includes renowned guest faculty and training in research such as Good Clinical Practice (GCP) protocol oversight, Institutional Review Board reporting, safety management and practical applications in the clinical trial environment.
  •  
  •   A "New to Research" Track
    Provides skills training for physicians who are interested in pursuing clinical research.
  •  
  •   An "Enhanced Research" Track
    Enhanced skills training for physicians with some knowledge and experience in clinical research.
  •  

"Clinical trials are the basis of modern medicine and have the power to drive innovative therapies to fight diseases. Today, women and populations from under-resourced communities are vastly underrepresented in clinical trials," said Lisa Earnhardt , executive vice president, Medical Devices, Abbott, and the co-executive sponsor for the company's Diversity in Research steering committee that she leads alongside Andrea Wainer , executive vice president, Rapid and Molecular Diagnostics, Abbott. "Through our new partnership with the Women as One CLIMB Research skills training program, we are actively changing the trajectory of how underrepresented physicians address clinical trial care for underrepresented groups."

 

The collaboration with Women as One is the latest addition to Abbott's broad corporate initiative designed to improve diversity in medical research. A key focus of the company's efforts is to increase the number of diverse investigators leading trial sites, a situation that compounds the challenges of increasing enrollment into clinical studies. The new training program is open to underrepresented groups including female, Black, Native American, Asian, South Asian, Hispanic and non-binary cardiologists.

 

Abbott provided funding of $150,000 for the CLIMB Research program which adds to the more than $5 million Abbott has committed since last year, which includes nearly 300 scholarships to medical schools at Historically Black Colleges and Universities (HBCUs) and minority nursing associations. The company has also established a Diversity in Clinical Trials Medical Advisory Board and dedicated funding to increase diversity enrollment within Abbott trials.

 

"Women and underrepresented groups are too often absent from industry-driven activities. Enhancing the representation of these groups leading clinical trials will have a direct impact on the number of diverse trial participants," said Roxana Mehran, M.D., Women as One Founding director. "By advancing our training program with Abbott, we are actively increasing the number of diverse researchers in clinical trials to create a safe haven of trust to ultimately support underrepresented patients."

 

CLIMB Research 2022 is co-sponsored by the Global Cardiovascular Clinical Trialists (CVCT) Forum. CVCT is a unique annual educational forum aimed at discussing the latest and most critical cardiovascular, cardiorenal and cardiometabolic trials. In line with the goals of CVCT to increase the number of underrepresented individuals in cardiovascular clinical trial leadership, CVCT is an active collaborator on CLIMB Research.

 

To learn more about Women as One Climb Skills Training program #TIMETOCLIMB sponsored by Abbott, visit: womenasone.org/CLIMB2022

 

  About Abbott:  

 

Abbott is a global health care leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of health care, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines. Our 113,000 colleagues serve people in more than 160 countries.

 

Connect with us at www.abbott.com , on LinkedIn at www.linkedin.com/company/abbott-/ , on Facebook at www.facebook.com/Abbott and on Twitter @AbbottNews .

 

  1 Clark, L.T., et al., Increasing Diversity in Clinical Trials: Overcoming Critical Barriers. Curr Probl Cardiol, 2019. 44 (5): p. 148-172.

 

  2 Yates, Byrne, Susan Donahue , Linda McCarty , & Mathews, 2020.

 

 Cision View original content: https://www.prnewswire.com/news-releases/abbott-and-women-as-one-partner-to-help-more-underrepresented-physicians-lead-clinical-trials-301544824.html  

 

SOURCE Abbott

 
 

News Provided by PR Newswire via QuoteMedia

ABT
The Conversation (0)
Abbott Announces New Partnerships and Programs to Advance its Diversity in Clinical Trials Initiative

Abbott Announces New Partnerships and Programs to Advance its Diversity in Clinical Trials Initiative

 
 
  • New efforts focus on research infrastructure, continued training of diverse clinical research personnel and improved diversity within Abbott's own clinical trials
  •  
  • Abbott's Diversity in Clinical Trials initiative aligns with the company's continued focus for greater health equity, expanded access, affordability and removing barriers to life-saving technology and innovation
  •  
  • The new programs build on a successful first year of the multi-million-dollar corporate initiative
  •  

Abbott (NYSE: ABT) today announced a series of new programs within its multi-million-dollar initiative to increase diversity in clinical trials and improve care among under-represented populations. The new additions to Abbott's Diversity in Clinical Trials initiative build on the partnerships, scholarships, and the focus on diversified participants in the company's own clinical trials during the initiative's first year.

 

The latest programs include the launch of a new initiative with the Norton Healthcare Foundation to build and implement new models of sustainable clinical research alongside the Institute for Health Equity, a Part of Norton Healthcare in Louisville, Ky. ; a new training program for clinical research coordinators in partnership with Barnett International; and a newly-created Diversity in Research Office at Abbott focused on ensuring diverse representation in clinical trials.

 

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less
richard murray md

Avisa Diagnostics Appoints Dr. Richard Murray as Chief Medical Officer

 

Avisa Diagnostics Inc. (CSE:AVBT) (Avisa), a clinical-stage medical device company developing an ultra-rapid, point-of-care biomarker breath test for the detection and monitoring of virulent bacterial lung infections, is pleased to announce that the Company has hired Richard K. Murray, M.D., to the newly created position of Chief Medical Officer (CMO).

 

Dr. Murray has over 25 years of industry experience. He worked at Merck & Co. for many years in positions of increasing responsibility, in a variety of business, medical and scientific areas. His most recent position was Vice President and Deputy Chief Patient Officer. Dr. Murray was also a Fellow at the Advanced Leadership Initiative at Harvard University. He has managed all areas of medical affairs, including outcomes research, medical information, professional and academic affairs, field-based medical physicians, and investigator-initiated trials globally. Prior to his industry career, he was a practicing physician in cardiovascular-pulmonary medicine and an asthma researcher at the Hospital of the University of Pennsylvania. Dr. Murray has an M.D. from Howard University and an M.A. in Chemistry and A.B. in Psychology from Clark University. Dr. Murray currently is Board Chair of the Asthma and Allergy Foundation of America.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
illustration of brain and cell phone.

BlinkLab Completes First Patient Test for US Autism Diagnostic Study

Digital healthcare company BlinkLab (ASX:BB1) has tested the first patient in its US autism diagnostic study, which is geared at validating the company's Dx1 test as a diagnostic aid for clinicians.

BlinkLab states in its Wednesday (March 12) release that the study is the largest digital diagnostic trial for autism in the US, with its aim being to support the early detection of developmental conditions like autism.

The first patient test took place at PriMED Clinical Research in Dayton, Ohio. PriMED, a division of PriMED Physicians, is one of two clinical sites selected for the study’s initial phase, which is targeting 100 patients.

Keep reading...Show less
HeraMED Signs Strategic Collaboration Agreement with Garmin Health

HeraMED Signs Strategic Collaboration Agreement with Garmin Health

HeraMED Limited (ASX: HMD), a medical data and technology company leading the digital transformation of maternity care, is delighted to announce it has entered into a collaboration agreement with Garmin (NYSE: GRMN), a leading global provider of smartwatches and GPS-enabled products, aimed at enhancing remote pregnancy monitoring and expanding the range of health data available to expectant mothers and their healthcare providers.

Keep reading...Show less
Cardiologist wearing virtual reality glasses.

2 Biggest Medical Device ETFs in 2025

Exchange-traded funds (ETFs) are a popular investment strategy, and generally contain a variety of publicly traded companies under one stock symbol, often with a focus on a specific sector.

Depending on the ETF, investors may be able to track up-and-coming companies, get exposure to top firms or a mix of both. Aside from stocks, some ETFs also track commodities or bonds.

In the healthcare industry, medical device ETFs bring together companies that go to great lengths to develop pharmaceutical-based technology that can improve the lives of patients.

Keep reading...Show less
Cyclomedica

Cyclopharm Signs US Agreement with HCA Healthcare for Technegas®

Cyclopharm Limited (ASX: CYC) is pleased to announce the signing of a major contract with Hospital Corporation of America Healthcare (HCA), one of the largest single healthcare providers in the United States. This agreement marks a significant milestone for the company which will allow the deployment of Technegas® in up to 169 nuclear medicine departments across HCA’s extensive network.1

Keep reading...Show less
CONNEQT App Launches in USA as Pulse Deliveries Commence

CONNEQT App Launches in USA as Pulse Deliveries Commence

Cardiex Limited (CDX:AU) has announced CONNEQT App Launches in USA as Pulse Deliveries Commence

Download the PDF here.

Female doctor with clipboard talking to smiling female patient at hospital.

Revolutionizing Women's Health: Antifungal Innovation Brings New Investment Opportunities

The intersection of women's health and antifungal innovation represents a pivotal moment in healthcare, offering both transformative medical advancements and compelling investment opportunities.

The groundbreaking developments in antifungal treatments specifically targeting women's health issues present a substantial market potential, resulting in rising investor interest in this rapidly evolving sector.

Despite comprising half the global population, women face unique health challenges that have historically received insufficient attention and investment. Among these health challenges, vaginal candidiasis stands out as a persistent and widespread issue affecting millions of women worldwide.

Keep reading...Show less

Latest Press Releases

Related News

×